Oculus Innovative Sciences Inc. (NASDAQ: OCLS) is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care.
The company's Microcyn technology is based on electrically charged oxychloridne small molecules designed to target a wide range of pathogens that cause disease. Its products have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses.
So far, the company has obtained eleven 501(k) clearances from the U.S. FDA to sell its products as medical devices and has launched at least one new dermatology product per quarter in FY 2016.
Download a free SECFilings Company Analysis on Oculus Innovative Sciences Inc. that covers:
Enter your e-mail below to receive the free analysis: